1.
ACS Med Chem Lett
; 11(4): 497-505, 2020 Apr 09.
Artículo
en Inglés
| MEDLINE
| ID: mdl-32292556
RESUMEN
A combination of focused library and virtual screening, hit expansion, and rational design has resulted in the development of a series of inhibitors of RETV804M kinase, the anticipated drug-resistant mutant of RET kinase. These agents do not inhibit the wild type (wt) isoforms of RET or KDR and therefore offer a potential adjunct to RET inhibitors currently undergoing clinical evaluation.